We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S.
Read MoreHide Full Article
OPKO Health, Inc.(OPK - Free Report) announced the launch of its kidney drug Rayaldee (calcifediol). The company said it will begin shipping of the drug to distributors in the United States on Nov 29, 2016. Rayaldee extended release capsules were approved by the FDA in June this year for treating secondary hyperparathyroidism (SHPT) in patients above 18 years with stage III or IV chronic kidney disease (CKD). The product will be available nationwide at retail pharmacies from Nov 30.
Rayaldee was introduced to nephrologists at the American Society of Nephrology (ASN) Kidney Week Meeting held last week in Chicago. Rayaldee is the first product developed by OPKO Health. The product has side effects like anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation. However, this launch is expected to immensely help patients with CKD.
OPKO Health is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the healthcare sector include Heska Corporation , Arbutus Biopharma Corporation (ABUS - Free Report) and Anika Therapeutics Inc. (ANIK - Free Report) . Heska sports a Zacks Rank #1 (Strong Buy) while Arbutus and Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 per share to $1.35 for 2016 and from $1.38 per share to $1.53 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 301.64%. Share price has increased 93.31% year to date for the company.
Arbutus’ loss estimates narrowed from $2.15 to $1.74 per share for 2016 and from $1.96 to $1.51 per share for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Anika’s earnings estimates increased from $1.96 per share to $2.06 for 2016 and from $2.03 per share to $2.09 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 33.14%. Share price has increased 13.42% year to date for the company.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S.
OPKO Health, Inc.(OPK - Free Report) announced the launch of its kidney drug Rayaldee (calcifediol). The company said it will begin shipping of the drug to distributors in the United States on Nov 29, 2016. Rayaldee extended release capsules were approved by the FDA in June this year for treating secondary hyperparathyroidism (SHPT) in patients above 18 years with stage III or IV chronic kidney disease (CKD). The product will be available nationwide at retail pharmacies from Nov 30.
Rayaldee was introduced to nephrologists at the American Society of Nephrology (ASN) Kidney Week Meeting held last week in Chicago. Rayaldee is the first product developed by OPKO Health. The product has side effects like anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation. However, this launch is expected to immensely help patients with CKD.
OPKO HEALTH INC Price
OPKO HEALTH INC Price | OPKO HEALTH INC Quote
OPKO Health is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the healthcare sector include Heska Corporation , Arbutus Biopharma Corporation (ABUS - Free Report) and Anika Therapeutics Inc. (ANIK - Free Report) . Heska sports a Zacks Rank #1 (Strong Buy) while Arbutus and Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 per share to $1.35 for 2016 and from $1.38 per share to $1.53 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 301.64%. Share price has increased 93.31% year to date for the company.
Arbutus’ loss estimates narrowed from $2.15 to $1.74 per share for 2016 and from $1.96 to $1.51 per share for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Anika’s earnings estimates increased from $1.96 per share to $2.06 for 2016 and from $2.03 per share to $2.09 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 33.14%. Share price has increased 13.42% year to date for the company.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>